Fibromyalgia and myofascial pain syndrome-a dilemma

H C Chandola, Arunangshu Chakraborty, H C Chandola, Arunangshu Chakraborty

Abstract

Pain and fatigue associated to the musculoskeletal system are among the leading causes of patients to visit their physicians and nearly one-third of such patients suffer from fibromyalgia. Fibromyalgia syndrome (FMS) is a chronic debilitating disorder characterized by widespread pain with tenderness in specific areas, leading to fatigue, headache and sleep disorder. Myofascial Pain Syndrome (MPS), is also a localized musculoskeletal pain producing condition whose diagnostic and management criteria differ from FMS but still considered by many only a subtype of FMS. Till date no exact cause has been held responsible for these painful conditions, therefore treatment of these disorders is always a challenge. The therapies are not precise but multimodal including pharmacological and alternative approaches. This article describes the existing knowledge pertaining to these conditions in regard of causative factors diagnosis and management.

Keywords: Fibromyalgia; Myofascial pain; Taut bands; Trigger points.

Figures

Fig 1
Fig 1
Summary of skeletal muscle structure:

References

    1. Robert B Salter. Textbook of disorders and injuries of the musculoskeletal system. 3rd edition. Lippincott Williams and Wilkins; 1999. Normal structure and function of musculoskeletal tissues; p. 23.
    1. Victoria Wapf, Andre Busato. Main health related problems patients attended their physicians for. BMC complementary and alternative medicine. 2007;7:41.
    1. Schneider M, Veron H, Ko G, Lawson G, et al. Chiropractic management of fibromyalgia syndrome, a systematic review of the literature. J Manipulative Physiol Ther. 2009;32:25–40.
    1. Harris RE, Sundgren PC, Pang Y, Hsu M, et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum. 2008;58:903–7.
    1. ICD version 2007: World Health Organization online resource.
    1. Cummings M, Baldry P. Regional myofascial pain: diagnosis and management. Best Practice & Research in Clinical Rheumatology. 2007;21:367–387.
    1. Hans SC, Harrison P. Myofascial pain syndrome and trigger point management. Reg Anesth. 1999;22:89–101.
    1. Leesa P Huquenin. Myofascial trigger point: the current evidence. Physical Therapy in Sport. 2004;5:2–12.
    1. Valencia M, Alonso B, Alvarez MJ, Barrientos MJ, et al. Effects of 2 physiotherapy programs on pain perception, muscular flexibility, and illness impact in women with fibromyalgia: a pilot study. J Manipulative Physiol Ther. 2009;32:84–92.
    1. Saber AA, Boros MJ, Mancl T, Elgamal MH, et al. The effect of Roux-en-Y bypass on fibromyalgia. Obes Surg. 2008;18:652–5.
    1. Weingarten TN, Podduturu VR, Hooten WM, Thompson JM, et al. Impact of tobacco use in patients presenting to a multidisciplinary outpatient treatment program for fibromyalgia. Clin J Pain. 2009;25:39–43.
    1. Peggy A Houglum. Therapeutic Exercise for Musculoskeletal Injuries. 2nd ed. Human Kinetics; 2005. Myofascial Trigger Points; p. 165.
    1. Rachlin ES. Myofascial Pain and Fibromyalgia Trigger Point Management. St Louis, Mosby- Yearbook: 1994. History and physical examination for regional myofascial pain syndrome; p. 169.
    1. Simmons D, Travell J, Simmons Y. Trigger Point Manual. 2nd edition. vol-1. Williams & Wilkins; 1999. p. 132.
    1. Wang H, Buchner M, Moser MT, Daniel V, et al. Circulating cytokine levels compared to pain in patients with fibromyalgia. Clin J Pain. 2009;25:1–4.
    1. Zhang Z, Cherryholmes G, Mao A, Marek C. High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. Exp Biol Med. 2008;233:1171–80.
    1. Klingmann PO, Kugler J, Steffke Ts, Bellingrath S. Sex specific prenatal programming: a risk for fibromyalgia? Ann N Y Acad Sci. 2008;1148:446–55.
    1. Hong CZ. Considerations & recommendations regarding myofascial trigger point injection. J Mus Pain. 1994;2:29–59.
    1. Richard, Weiner S, editors. Pain Management. 6th ed. CRC Press; 2006. American Academy of Pain Management. Manual Therapy (of Myofascial Pain) p. 238.
    1. Lucy W Ferguson, Robert Gerwin. Clinical Mastery in the Treatment of Myofascial Pain. Lippincott Williams & Wilkins; 2004. Abdominal Pain of Myofascial Origin; p. 320.
    1. Charles E Argoff. A review of the use of topical analgesics for myofascial pain. Current Pain & Headache Reports. 2002;6:375–378.
    1. Di Munno O, Valentini G, Bianchi G, et al. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol. 2007;25:182–8.
    1. Jabbari B. Botulinum neurotoxins in the treatment of refractory pain. Nat Clin Pract Neurol. 2008;4:676–85.
    1. Jeynes LC, Gauci CA. Evidence for the use of botulinum toxin in the chronic pain setting-a review of the literature. Pain Pract. 2008;8:269–76.
    1. Rao SG, Clauw DJ. The management of fibromyalgia: Drugs Today (Barc) 2004;40:539–54.
    1. Lyseng-Williamson KA, Siddiqui MA. Pregabalin: A review of its use in fibromyalgia. Drugs. 2008;68:2205–23.
    1. Owen RT. Pregabalin: Its efficacy, safety and tolerability profile in FMS. Drugs Today (Barc) 2007;43:857–63.
    1. Russel IJ, Mease PJ, Smith TR, Kajdasz DK. Efficacy and safety of duloxetine for treatment of fibromyalgia. Pain. 2008;136:432–44.
    1. Owen RT. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today. 2008;44:653–60.
    1. Mease PJ, Clauw DJ, Gendreau RM, Rao SG, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. J Rheumatol. 2009;36:398–409.
    1. Spath M, Stratz T, Neeck G, Kotter I, et al. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol. 2004;33:267–270.
    1. Holman AJ. Pragmatic consideration of recent randomized, placebo-controlled clinical trials for treatment of fibromyalgia. Curr Pain Headache Rep. 2008;12:393–8.
    1. Samborski W, Lezanska-Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry. 2004;37:168–70.
    1. See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician. 2008;78:365–70.
    1. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004;51:9–13.
    1. Alentorn-Geli E, Padilla J, Moras G, Lázaro Haro C, et al. Six weeks of whole-body vibration exercise improves pain and fatigue in women with fibromyalgia. J Altern Complement Med. 2008;14:975–81.
    1. Schneider M, Vernon H, Ko G, Lawson G, Perera J. Chiropractic management of fibromyalgia syndrome: a systematic review of the literature. J Manipulative Physiol Ther. 2009;32:25–40.
    1. David H. Healing Fibromyalgia. John Wiley & Sons; 2007. Trock, Frances Chamberlain. Tools for managing your fibromyalgia; p. 159.
    1. Matsushita K, Masuda A, Tei C. Efficacy of Waon therapy for fibromyalgia. Intern Med. 2008;47:1473–6.
    1. Lee SH, Chen CC, Lee CS, et al. Effects of needle electrical intramuscular stimulation on shoulder and cervical myofascial pain syndrome and microcirculation. J Chin Med Assoc. 2008;71:200–6.
    1. Matsutani LA, Marques AP, Ferreira EA, Assumpção A, et al. Effectiveness of muscle stretching exercises with and without laser therapy at tender points for patients with fibromyalgia. Clin Exp Rheumatol. 2007;25:410–5.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit